(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -24.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Arrowhead Pharmaceuticals's revenue in 2026 is $1,090,981,000.On average, 15 Wall Street analysts forecast ARWR's revenue for 2026 to be $65,050,553,543, with the lowest ARWR revenue forecast at $42,953,473,961, and the highest ARWR revenue forecast at $94,101,631,680. On average, 14 Wall Street analysts forecast ARWR's revenue for 2027 to be $45,906,752,848, with the lowest ARWR revenue forecast at $15,672,402,705, and the highest ARWR revenue forecast at $70,282,156,161.
In 2028, ARWR is forecast to generate $77,385,989,160 in revenue, with the lowest revenue forecast at $43,914,094,784 and the highest revenue forecast at $119,979,580,392.